TX-ABB
9.10.2019 17:02:09 CEST | Business Wire | Press release
ABB today opened its first global healthcare research hub on the Texas Medical Center (TMC) campus, in Houston, Texas – showcasing a number of concept technologies, including a mobile YuMi® robot, which will be designed to assist medical and laboratory staff with laboratory and logistics tasks in hospitals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191009005527/en/
The dual-arm mobile YuMi® will be able to sense and navigate its way around its human co-workers autonomously, while learning to find different routes from one location to another. It has the potential to undertake a wide range of repetitive and time-consuming activities, including preparation of medicines, loading and unloading centrifuges, pipetting and handling liquids and picking up and sorting test tubes.
The mobile YuMi®could also be used in hospitals for a wide variety of logistics roles. YuMi® may be able to dispense medicines, transport them to where they are needed in hospitals, bring medical supplies to hospital staff and bed linen direct to patients’ bedrooms.
At TMC Innovation Institute, ABB will develop robots that are able to carry out repetitive, delicate and mundane processes, leaving highly skilled medical and laboratory staff free to undertake more valuable roles and ultimately treat more patients. ABB analysis shows that repetitive tasks could be completed up to 50 per cent faster with automation, compared to current manual processes, with the added benefit that robots can work 24 hours a day.
“The healthcare sector is undergoing significant transformation as the diagnosis and treatment of disease advances, while coping with an aging population, increasing costs and a growing worldwide shortage of medical staff. With our new healthcare research and development hub at TMC we are aiming to develop answers to these challenges – together with the best minds in academia, science and medicine,” said Sami Atiya, President of ABB’s Robotics and Discrete Automation business. “Our experience in industrial and collaborative robotics will give us a strong basis to be able to adapt flexible automation to the healthcare sector. Together with our partners at TMC, we will develop cutting-edge robotics solutions. We are working to reduce the number of manual procedures performed by medical staff, improve the accuracy of laboratory work and enhance patient satisfaction and ultimately patient safety.”
Other technologies showcased by ABB at the Healthcare Research Hub include YuMi® robots that could aid in centrifuge tending and test tube handling systems, and an IRB 1200 robot that could execute liquid transfers in a pipetting application. All are common medical laboratory tasks that robotic automation may be able to support by combining consistent performance with a level of flexibility and continuous operation that could increase throughput and quality while minimizing costs.
TMC is the largest medical city in the world with world-class collaborative research resources, including some of the world’s leading companies and hospitals. ABB’s new 5,300 sq ft (500m2 ) Healthcare Hub will be housed at the TMC Innovation Institute, a state-of-the-art hub that fosters collaboration of medicine and cutting-edge technology, connecting start-ups with pioneers in academia and leading technology companies in order to accelerate the development and prototyping of breakthrough medical technology.
“Texas Medical Center, TMC Innovation, and the entire TMC network of member institutions are pleased to welcome ABB on the occasion of its first foray into the healthcare space with this incredible and unprecedented new robotics facility,” emphasized Bill McKeon, President & CEO of Texas Medical Center. He added, “A primary goal across TMC – the largest medical city in the world – is to make research happen faster while simultaneously cutting costs in order to create more rapid and cost-effective solutions for patients who are in desperate need of treatment. ABB’s move into the heart of the Texas Medical Center campus with this first-of-its-kind R&D facility for creating robotics solutions in healthcare will set a new course for advancements in medicine and establish TMC as the nexus for a new kind of synergistic partnership that will shape the future of healthcare for clinicians, researchers, and patients alike.”
Robotic automation in the healthcare sector offers significant opportunity for future growth. According to internal ABB research, the global market is estimated to reach nearly 60,000 non-surgical medical robots by 2025, a fourfold increase from 2018.
Watch the video: https://youtu.be/SA_1vfH5UIk
Media b-roll: https://drive.google.com/file/d/13r9gjaXpLCZmJ69m6m6YyVDM9ONkauQO/view
ABB (ABBN: SIX Swiss Ex) is a technology leader that is driving the digital transformation of industries. With a history of innovation spanning more than 130 years, ABB has four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by the ABB Ability™ digital platform. ABB’s Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 147,000 employees. www.abb.com
ABB Robotics is a pioneer in industrial and collaborative robots and advanced digital services. As one of the world’s leading robotics suppliers, we are active in 53 countries and over 100 locations and have shipped over 400,000 robot solutions for a diverse range of industries and applications. We help our customers to improve flexibility, efficiency, safety and reliability, while moving towards the connected and collaborative factory of the future. www.abb.com/robotics
TMC INNOVATION
Texas Medical Center (TMC)—the largest medical city in the world—is at the forefront of advancing life sciences. Home to the brightest minds in medicine, TMC nurtures cross-institutional collaboration, creativity, and innovation among its 106,000-plus employees. With a campus of more than 50 million square feet, TMC annually hosts 10 million patients, performs over 180,000 surgeries, conducts over 750,000 ER visits, performs close to 14,000 heart surgeries, and delivers over 25,000 babies. Beyond patient care, TMC is pushing the boundaries of clinical research across its extensive network of partner institutions on a daily basis, pioneering effective health policy solutions to address the complex health care issues of today, and cultivating cutting-edge digital health applications and medical devices. For more information, please visit www.tmc.edu .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191009005527/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom